The extreme genetic heterogeneity of nonsyndromic hearing loss (NSHL) makes genetic diagnosis expensive and time consuming using available methods. To assess the feasibility of targetenrichment and massively parallel sequencing technologies to interrogate all exons of all genes implicated in NSHL, we tested nine patients diagnosed with hearing loss. Solid-phase (NimbleGen) or solution-based (SureSelect) sequence capture, followed by 454 or Illumina sequencing, respectively, were compared. Sequencing reads were mapped using GSMAPPER, BFAST, and BOWTIE, and pathogenic variants were identified using a custom-variant calling and annotation pipeline (ASAP) that incorporates publicly available in silico pathogenicity prediction tools (SIFT, BLOSUM, Polyphen2, and Align-GVGD). Samples included one negative control, three positive controls (one biological replicate), and six unknowns (10 samples total), in which we genotyped 605 single nucleotide polymorphisms (SNPs) by Sanger sequencing to measure sensitivity and specificity for SureSelect-Illumina and NimbleGen-454 methods at saturating sequence coverage. Causative mutations were identified in the positive controls but not in the negative control. In five of six idiopathic hearing loss patients we identified the pathogenic mutation. Massively parallel sequencing technologies provide sensitivity, specificity, and reproducibility at levels sufficient to perform genetic diagnosis of hearing loss.
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deafness | genomics | Usher syndrome | diagnostics | next-generation sequencing H ereditary sensorineural hearing loss (SNHL) is the most common sensory impairment in humans (1, 2) . In developed countries, two-thirds of prelingual-onset SNHL is estimated to have a genetic etiology, of which ∼70% is nonsyndromic hearing loss (NSHL). Eighty percent of NSHL is autosomal recessive nonsyndromic hearing loss (ARNSHL), ∼20% is autosomal dominant (AD), and the remainder is composed of X-linked and mitochondrial forms (1, 3) . To date, 134 deafness loci have been identified, and 32 recessive (DFNB), 23 dominant (DFNA) and 2 X-linked (DFNX) genes have been cloned; 8 genes are associated with both ARNSHL and ADNSHL (4) .
Establishing a genetic diagnosis of NSHL is a critical component of the clinical evaluation of deaf and hard-of-hearing persons and their families. If a genetic cause of hearing loss is determined, it is possible to provide families with prognostic information, recurrence risks, and improved habilitation options. For persons diagnosed with Usher syndrome, preventative measures including sunlight protection and vitamin therapy can be implemented to minimize the rate of progression of retinitis pigmentosa (5) . Most current genetic testing strategies for NSHL rely on a gene-specific Sanger sequencing approach. Because mutations in a single gene, GJB2 (DFNB1), account for up to 50% of ARNSHL in many world populations (6) , this approach has changed the evaluation of patients with presumed ARNSHL. However, the mutation frequency in other genes in persons with NSHL in outbred populations is unknown, making sequential gene screening problematic (7) . The extreme heterogeneity of NSHL also makes serial sequencing approaches unfavorable in terms of efficiency and cost.
The advent of new technologies that target and enrich specific regions of the genome coupled with massively parallel sequencing offers an alternative approach to genetic testing for deafness. Although genetic diagnoses can also be made by whole genome sequencing (8) or targeted sequence capture of the entire exome (9, 10) , these approaches are expensive, and time-consuming data analysis is required. Therefore, our aim was to develop and test a streamlined, comprehensive genetic diagnostic platform that targets only the 0.014% of the genome currently associated with NSHL.
Results
We elected to compare the two most widely used target enrichment approaches (NimbleGen solid-phase and SureSelect solutionbased sequence capture) and two massively parallel sequencing technologies (454 GS FLX pyrosequencing and Illumina GA II cyclic reversible termination sequencing) using genomic DNA from NSHL families. The optimized platform and diagnostic pipeline, which we refer to as OtoSCOPE (otologic sequence capture of pathogenic exons), targets the exons of all 54 known deafness genes (Table S1 ). The subjects were nine individuals with presumed NSHL (Table 1 ). Sanger sequencing-based genetic testing had been completed for GJB2 and SLC26A4 in all autosomal recessive (AR) cases. Positive controls had been genetically diagnosed by Sanger sequencing prior to this study.
We performed array and solution-based targeted capture of all exons of the 54 genes known to cause NSHL, also including Usher syndrome genes because in infants and children, Usher syndrome is not readily distinguishable from ARNSHL (Materials and Methods and Table S1 ). Some requested target regions were not covered by the NimbleGen and SureSelect designs (9.3% and 8.3%, respectively; Table 2 ) due to repetitive regions. These percentages are consistent with other reports focused on exon sequence capture (11, 12) . However, the proportion of protein coding regions included in the SureSelect bait design was comparatively better than that covered by NimbleGen (97.7 and 93.6%, respectively; Table  2 ), reflecting different methods for defining repetitive regions and complementary oligonucleotide selection.
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Candidate variants follow inheritance pattern (if known) and are predicted deleterious by Polyphen2, SIFT, BLOSUM62, and align-GVGD. Candidate mutations were ruled out or in by segregation analysis and/ or presence in controls. Causative mutations are predicted damaging, segregate with hearing loss in family, are not found in controls, and/or are known to cause hearing loss. NSHL, nonsyndromic hearing loss; ADNSHL, autosomal dominant nonsyndromic hearing loss; ARNSHL, autosomal recessive nonsyndromic hearing loss; Pos Ctrl, positive control; RO-segregation, mutation ruled out by segregation analysis; ROcontrols, mutation ruled out by controls analysis. *Previously reported (16 We paired NimbleGen solid phase sequence capture with 454 GS FLX pyrosequencing (NimbleGen-454 method) and SureSelect solution-based sequence capture with Illumina GAII sequencing (SureSelect-Illumina method) to determine the efficacy of these approaches for clinical diagnostics. Samples 1 and 2 were sequenced using both the NimbleGen-454 and SureSelectIllumina to provide direct comparison of these methods, whereas samples 3-10 were examined only using SureSelect-Illumina.
The results of our study show that due to the disparity in sequence output between the two sequencing platforms (13), the overall sequence depth of coverage was on average 13-fold higher for the SureSelect-Illumina method as compared with the NimbleGen-454 method (903× and 71× depth of coverage, respectively (Materials and Methods); Table 3 ). However the percent of on-target reads (i.e., capture efficiency) was significantly lower (P < 0.0001) for the SureSelect-Illumina method (average 19.6%) than the NimbleGen-454 method (average 64.2%), which may reflect PCR-induced bias during Illumina library preparation, small target size, and sequencer oversaturation (Tables 2 and 3) .
As a threshold for variant detection, we required ≥3 reads (multidirectional) for 454 and ≥40 reads for Illumina, with the added stipulation that the variant had to be present in at least 30% of reads to be considered high quality. Similar thresholds have been used in other studies (14) and reflect the need for high sensitivity in diagnostic testing (false positives are preferred over false negatives) (15) . At these thresholds, 96.0% and 95.3% of protein coding bases were covered by the NimbleGen-454 and SureSelect-Illumina platforms, respectively (Table 2) .
To validate the platforms as diagnostic tests we genotyped 605 highly heterozygous SNPs (average heterozygosity, 0.46; average 55 SNPs per sample) in the targeted regions by Sanger sequencing. Homozygous-alternative allele calls (n = 149; average 14 per sample) and heterozygous allele calls (n = 199; average 18 per sample) were used as true positive variants; homozygousreference allele calls (n = 257; average 23 per sample) were used as true negative variants (simulated nonvariants). Variants not covered at variant-calling threshold for either platform were considered false negatives.
With both the NimbleGen-454 and SureSelect-Illumina methods, we identified the causative mutations in samples 1 and 2. Specificity was ∼98% for NimbleGen-454 and >99% for SureSelect-Illumina (Table 3 ). For the SureSelect-Illumina method, one false negative was found across all 10 samples (sensitivity 99.72%) reflecting high coverage depth of targeted regions. For the NimbleGen-454 method, a mean depth of coverage of 71× was associated with an increased false-negative rate (average two per sample) and a decrease in sensitivity (93.98%). This difference may be attributable to a relatively lower quality depth-of-coverage threshold for the NimbleGen-454 method (3× versus 40× for SureSelect-Illumina) as mean sequence coverage for protein-coding sequence was similar.
On the basis of data from samples 1 and 2, we analyzed the remaining eight samples using the SureSelect-Illumina method and a sequence analysis protocol we developed (Materials and Methods). In total, we detected causative mutations in the three positive controls and in five of six persons with idiopathic hearing loss ( Table 1) . Analysis of controls (samples 1-4) was completed in a blinded fashion with only the mode of inheritance known. Sample 1 was from a family segregating ADNSHL. Of three candidate variants, the known hearing loss mutation in COCH (c.151C > T, p.P51S, rs28938175; DFNA9) was the only variant that segregated with the phenotype in this family (16) . In samples 2 and 3 (biological replicates), the only candidate variant determined in each sample was the known deafness mutation in GJB2 (c.109G > A, p.V37I; DFNB1) (17) . In sample 4, the negative control, none of the nine nonsynonymous/splice site/indel variations identified was predicted to be pathogenic.
Of the six persons with idiopathic hearing loss, two were from families segregating ARNSHL. Sample 5 was from a person with profound SNHL who was shown to carry a variant of unknown significance (VUS) in STRC (c.4057C > T, p.Q1353×; rs2614824; DFNB16) in 44/47 Illumina reads. This variant was not observed Values given are a mean of all samples for each method. *The same bases were requested for targeting using either NimbleGen or SureSelect and default repetitive regions were avoided in both methods.
† Variant calling threshold: for Illumina-SureSelect, 40× coverage and >30% of reads; for 454, ≥3× reads (multidirectional) and >30% of reads. in 100 ethnically matched controls (200 chromosomes). A hemizygous deletion of ∼100 kb involving the STRC-ψSTRC region was also detected (Fig. 1) and independently verified by PCR and array-comparative genomic hybridization (CGH). Homozygosity for this contiguous gene deletion is known to cause autosomal recessive deafness-infertility syndrome (20) , making this person a compound heterozygote for a novel point mutation in STRC in trans with a large contiguous gene deletion that includes STRC (DFNB16). Sample 10, from a 4-y-old cochlear implant recipient with no family history of hearing loss, was compound heterozygous for known USH1D mutations in CDH23 (c.1096G > A, p.A366T; c.3293A > G, p.N1098S) (19) .
The remaining four samples were from families segregating ADNSHL. For these samples, we also used, when possible, the computer program AudioGene (21) as a phenotypic filter to predict probable ADNSHL genotypes on the basis of audiometric criteria through audioprofiling. Sample 6 carried two candidate variants in MYO6 (DFNA22). The missense mutation was ruled out by segregation analysis; however, the 4-bp deletion (c.862_865delACAA, p.D288DfsX17) segregated with the phenotype and was not found in 135 ethnically matched controls (270 chromosomes). Because the DFNA22 locus is not represented on AudioGene, phenotypic filtering was not applied; however, the phenotype was consistent with reported DFNA22 audioprofiles (22) . Sample 8 carried two candidate variants-one mutation was ruled out by segregation analysis and the other is a known ADNSHL mutation [(DFNA2) c.842C > T, p.L281S] in KCNQ4 (18). This finding was consistent with AudioGene analysis, which predicted DFNA2 as the most likely cause of hearing loss in this family. Sample 9 carried two candidate variants-both detected in MYH14-that segregated with the phenotype in the extended family. One mutation was ruled out by analysis of controls, whereas the other, a stop mutation (c.5893G > T, p.E1965×), was not found in 119 ethnically matched controls (238 chromosomes) and was consistent with the predicted DFNA4 audioprofile. Four candidate variants were detected in sample 7, all of which were ruled out by segregation analysis. AudioGene analysis predicted KCNQ4 (DFNA2) as the most likely cause of hearing loss in this family; however, no variants in KCNQ4 were identified in this analysis or by prior Sanger sequencing. This finding suggests that this family may segregate a novel genetic cause of ADNSHL, which is possible because causative genes have not been identified for more than half of the mapped ADNSHL loci (4).
Discussion
In this study, we identified NSHL mutations, three of which have not been reported, in eight of nine persons tested. Our sequencing results are consistent with other studies reporting utility of these technologies for diagnosis of other genetic diseases (11, 15, 23) and suggest that massively parallel sequencing is suitable for genetic testing of NSHL. A key concern for any diagnostic test is sensitivity, as it is critical that pathogenic mutations are not missed. This requirement could be viewed as a potential limitation of targetenrichment methodologies, as a significant portion of targeted bases in repetitive regions cannot be captured (Table 2) . However, this limitation must be weighed against the decreased cost and time in simultaneously sequencing a large number of genes.
Multiplexing samples offers the opportunity to increase throughput, but to maintain read depth, capture efficiency must be increased (24, 25) . Scalability and cost also must be considered for large-scale sequencing projects. Our results show that when adequate target coverage and depth of coverage are maintained, both the SureSelect-Illumina and NimbleGen-454 platforms offer relatively high specificity and sensitivity. However, the SureSelectIllumina method is superior in terms of scalability, cost, and increased sensitivity. Our results compare very favorably with recent reports of high-throughput diagnostic tests for NSHL that rely on primer extension arrays (26) or targeted resequencing arrays (27) , which are appealing due to low cost but are limited in terms of capacity (not all NSHL genes can be screened simultaneously) and therefore sensitivity.
In summary, we have demonstrated that OtoSCOPE has the potential to improve the efficiency of genetic testing for NSHL and Usher syndrome. Our results show that targeted capture plus massively parallel sequencing has a sensitivity and specificity comparable to Sanger sequencing. Comprehensive genetic screening for deafness using platforms like OtoSCOPE would allow clinicians to improve patient care by providing prognostic information and genetic counseling, and in cases like Usher syndrome, offer families preventative strategies to minimize the rate of progression of retinitis pigmentosa. Some of the novel habilitation options under development to slow progression of hearing loss are also gene and even mutation specific (28) , suggesting that comprehensive genetic testing will be an integral part of the care of deaf and hard-ofhearing patients in the future.
Materials and Methods
Patients. The subjects were nine individuals with presumed NSHL (Table 1) who provided informed consent for this study approved by the University of Iowa International Review Board. Detailed family histories, clinical evaluations, and audiograms were available for each patient.
Targeted Capture and DNA Sequencing. Genomic DNA (gDNA) was extracted from whole blood using standard procedures (29) , quality assessed on an agarose gel and spectrophotometer, and quantified using the Qubit (Invitrogen) system. Three or 5 μg of gDNA were used for the SureSelect or NimbleGen capture methods, respectively. Exons in all isoforms of the 54 known deafness genes were identified in the RefSeq and Ensembl databases using the University of California Santa Cruz table browser (http://genome.ucsc.edu/). An additional 50 bp of flanking intronic sequence were added to each exon and genomic intervals were merged using Galaxy software (http://galaxy.psu.edu). In total, we targeted 1,258 regions comprising 421,741 bp using both NimbleGen and SureSelect methods. The same genomic coordinates were sent to Roche for complementary oligonucleotide microarray design or uploaded to Agilent's eArray website for cRNA bait design.
DNA isolated using NimbleGen solid phase sequence capture was sequenced using 454 GS FLX pyrosequencing (454 Life Sciences); DNA obtained from SureSelect solution-based sequence capture was subjected to Illumina GA II sequencing (Illumina). In both cases sequencing was performed according to manufacturer's protocols.
Sequence Analysis. Sequencing depth of coverage was defined as the number of sequencing reads, which had been filtered and mapped, per base. Average depth of coverage for each sequencing method was defined as the total depth of coverage per base, averaged over all requested bases. Depth of coverage per variant was defined as number of reads in which a variant was seen divided by the total depth of coverage for that base.
To prioritize a VUS, we developed a ranking algorithm that included the variant-calling threshold for each platform, location within the targeted region, type of change (nonsynonymous, splice-site, or frameshift deletion) and observed population frequency if the VUS was a reported SNP (Table 4) . Other investigators have filtered variants on the basis of absence from the dbSNP database (9, 10, 14) , a criterion we did not include as several mutations known to cause hearing loss have been assigned RefSNP (RS) numbers. Instead, we filtered variants on the basis of quantitative data from dbSNP130 such that any variant with an allele frequency >1% was considered a benign polymorphism (excluding known ARNSHL-associated variants of GJB2), whereas any variant with an allele frequency <1% (or of unknown frequency) was investigated further. In addition, we developed an in-house list of nonpathogenic nonsynonymous variants located within the targeted genes that can be excluded due to their presence in more than one nonreplicate sample or the negative control (list available upon request).
Pathogenicity of a nonsynonymous, splice-site or insertion-deletion (indel) VUS was assessed using in silico mutation prediction software. We incorporated four algorithms (BLOSUM62, SIFT, PolyPhen2, and Align-GVGD) that have the highest positive predictive value (94.6%) when concordant (30) and we required concurrence in at least three of four prediction tools. We also prioritized gene variants in the context of inheritance pattern (i.e., genes known to cause ARNSHL or ADNSHL) ( Table 4 and Table S1 ). A phenotypic filter was applied to ADNSHL using a computer learning algorithm we have developed called AudioGene, which predicts probable genotypes on the basis of audiometric criteria by constructing audioprofiles (20) . Candidate mutations were verified by Sanger sequencing in the extended families and if unreported, excluded in ethnically matched controls. Data given are means (range) (refer to Table S2 for detailed analysis). NS, nonsynonymous; SS, splice site. *Variant calling threshold included only variants seen in 30% of reads and 40× Illumina depth of coverage or 3× multidirectional reads for 454. † Allele frequency data taken from dbSNP130. ‡ Individual unique variants excluded variants found in more than one sample in this study.
